Care Capital

Total investments

34

Average round size

27M

Portfolio companies

20

Rounds per year

1.55

Lead investments

5

Follow on index

0.41

Exits

13

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyDrug DiscoveryPharmaceuticalsOther Pharmaceuticals and BiotechnologyHealth CareHealth DiagnosticsMedical DeviceMedicalPharmaceuticalBiopharma

Summary

The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Princeton.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Anacor Pharmaceutical, Vaxart, MicroCHIPS. Among the most successful fund investment fields, there are Therapeutics, Pharmaceutical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Care Capital, startups are often financed by Rho Ventures, MedImmune Ventures, Domain Associates. The meaningful sponsors for the fund in investment in the same round are MedImmune Ventures, HealthCare Ventures, Domain Associates. In the next rounds fund is usually obtained by Rho Ventures, Pitango Venture Capital, MedImmune Ventures.

The common things for fund are deals in the range of 10 - 50 millions dollars. When the investment is from Care Capital the average startup value is 10-50 millions dollars. The important activity for fund was in 2010. The increased amount of exits for fund were in 2015. The fund is generally included in less than 2 deals every year. Comparing to the other companies, this Care Capital performs on 9 percentage points more the average number of lead investments. Considering the real fund results, this VC is 4 percentage points less often commits exit comparing to other organizations.

The current fund was established by David R. Ramsay, Jan Leschly, John Parker. Besides them, we counted 3 critical employees of this fund in our database.

Show more

Investments analytics

Analytics

Total investments
34
Lead investments
5
Exits
13
Rounds per year
1.55
Follow on index
0.41
Investments by industry
  • Biotechnology (29)
  • Pharmaceutical (20)
  • Health Care (14)
  • Medical Device (7)
  • Health Diagnostics (6)
  • Show 13 more
Investments by region
  • United States (28)
  • United Kingdom (1)
  • Israel (1)
Peak activity year
2010
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
19
Avg. valuation at time of investment
364M
Group Appearance index
0.97
Avg. company exit year
14
Avg. multiplicator
1.16
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Anacor Pharmaceutical 11 May 2005 Late Stage Venture 25M
Orqis Medical 27 Jun 2001 Early Stage Venture 5M
Rewaa | رواء 15 Sep 2019 E-Commerce, Software, Information Technology, Marketplace, Electronics, Telecommunications Seed 800K Riyadh Region, Saudi Arabia, Saudi Arabia

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.